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Why was the cohort set up?
Despite remarkable progress in the momentum generated by
the millennium development goals, the levels of neonatal
and maternal morbidity and mortality remain significantly
high.1 Annually, an estimated 2.5 million neonatal deaths,
2.6 million stillbirths and 289 000 maternal deaths occur
worldwide; south Asian and sub-Saharan African regions
bear the highest burden.2–4 Many low- and middle-income

countries (LMICs) experience a considerably diverging pattern of neonatal and maternal mortality, with more than half
of the deaths directly attributable to pregnancy-associated
complications such as pre-eclampsia, birth asphyxia, preterm
births, intrauterine growth restriction (IUGR) or congenital
anomalies.5 Although there are effective interventions to alleviate the consequences of these complications, there are few
preventive strategies, with limited effectiveness. To address
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Key Features

Asia aimed at studying the interactions between genes and a wide range of varying environmental exposures on key
pregnancy and birth outcomes.
• The cohort is well characterized for clinical, epidemiological and socio-economic information with harmonized data

collection across all sites. The samples were collected and stored following standard operating procedures and
provide an excellent opportunity for biological characterization.
• The cohort includes a total of 10 001 women enrolled between May 2014 and June 2018 across Sylhet-Bangladesh,

Karachi-Pakistan and Pemba Island-Tanzania, who have given birth to 9938 babies.
• Follow-up included three to four visits during pregnancy: at baseline, at 24–28 weeks, at 32–36 weeks and after 37

completed weeks of gestational age to collect routine epidemiological data and biological samples, and two
additional visits after birth: between 1 and 6 days after birth and the second one between 42 and 60 days of age, in
which the newborn’s samples were taken.
• The data set comprises a wide range of phenotypical data and environmental measures, biological samples, as well

as a multiplicity of outcomes from the mother, the fetus and the neonate.
• The AMANHI biobank data is available at the Department for Maternal, Newborn, Child and Adolescent Health, and

Ageing at the World Health Organization, which is the coordination centre of the study. Queries regarding the data
and potential collaborations can be sent to Dr Rajiv Bahl (bahlr@who.int).

such a challenge, a better understanding of the biological
mechanisms underlying the pathophysiology of adverse pregnancy outcomes and the identification of biomarkers to predict pregnant women at risk of adverse outcomes will allow
women to be preferentially referred to hospitals for more
complete work-up and management. This advancement in
the care of women and infants will substantially reduce the
rates of maternal, fetal and newborn morbidity and
mortality.5,6
Since the reporting of the sequencing of the human
genome, there has been a rise in the powerful highthroughput analysis of human genetic material that has
uncovered an avalanche of genome-wide association studies.7–9 Despite unrivalled progress in biomedicine, the discoveries were made in high-income countries (HICs) and
may not be entirely pertinent to other populations.
Variances between countries can alter the risks, severity
and pathophysiology of pregnancy-related adverse outcomes. Therefore, discovering and validating specific biomarkers in LMIC settings is fundamental to increasing
their clinical usefulness, and permitting the early assessment, timely referral and ideal management of pregnancyrelated adverse events.
Prior to recent initiatives such as the Human Heredity
and Health in Africa (H3Africa) by the National Institute
of Health, USA,10,11 only a few African countries had biobanks12,13 and there were almost none in South Asia.
Despite the rapidly increasing availability and progressively decreasing costs of these technologies, there are still

no biobanks available in Africa and South Asia with a focus on maternal, fetal and neonatal health.14 In an effort to
reduce the inequity in international research, promote capacity building and infrastructure, and switch research priorities, there is a need for biobanks in LMICs to investigate
the pathogenesis of maternal and child morbidity and
mechanisms of host resistance to maximize the public
health and clinical relevance of research activities.15,16
To this end, the Alliance for Maternal and Newborn
Health Improvement (AMANHI) initiative was created
with the primary goal of establishing well-characterized
harmonized cohorts of pregnant women and their babies
in sub-Saharan Africa and South Asia.17 A leading objective has been to broaden knowledge on key pregnancy and
birth outcomes on a sustained research platform, prove the
feasibility of the implementation of such initiatives in
LMICs and enhance capacity around biobanking. In doing
so, we hope to demonstrate the potential of biobanks for
reliable research into the main risk factors, morbidity and
mortality of the diseases relevant to LMICs. We utilize this
opportunity to study interactions between genes and a
wide range of varying environmental exposures in causing
diseases of several dimensions in LMICs.

Who is in the cohort and how often have
they been followed up?
To construct the AMANHI biobank cohort, households in
three sites (Sylhet-Bangladesh, Karachi-Pakistan and Pemba
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• The AMANHI Biobank cohort is a large cohort of pregnant women and their babies in sub-Saharan Africa and South
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are only to be used for the goal of improving maternal and
newborn health, and not for commercial purposes or for
personal or institutional financial gain through the generation of intellectual property. A mechanism has been established to assure that data and specimens are shared in a
manner that is consistent with the informed consent, that
the participants’ privacy and confidentiality are protected,
and that any future use of the data and specimens has
Institutional Ethics Committee approval.
The study has received ethical approval from the local
and institutional ethics committees of all the three sites:
ICDDR, B and John Hopkins University for Bangladesh,
Aga Khan University for Pakistan and ZAMREC and John
Hopkins University for Tanzania. The protocols were also
approved by the World Health Organization (WHO)
Ethics Review Committee and continuing approvals were
obtained each new year. There are no direct benefits of the
study to the participants.

What has been measured?
Epidemiological, clinical and phenotypic data
As presented in Table 1 and to further characterize the
women in the AMANHI cohort, information regarding
maternal characteristics and medical history such as previous obstetric and gynaecological history, birth defects and
congenital anomalies among previous babies, stillbirths
and IUGRs, risk factors and exposures (cigarette smoking,
alcohol ingestion, pregnancy physical work and the use of
narcotics or other drugs) were collected at baseline and in
the pregnancy visits.
During the pregnancy and postnatal visits, FWs gathered clinical data on the current pregnancy including maternal weight and height, morbidities and pregnancy
complications, depression screening (nine-question patient
health questionnaire) and exposure to risk factors such as
smoking, alcohol ingestion, strenuous physical work and
the use of narcotics and other drugs. A thorough nutritional assessment using a validated food-frequency questionnaire was carried out during one pregnancy visit.19
Urine dipstick examinations for proteinuria and bloodpressure recordings using a MicrolifeV WatchBPV Home
monitor were undertaken at each visit. Table 2 summarizes
the main medical history and clinical characteristics of the
AMANHI cohort.
R

Ethical considerations
FWs consented pregnant women, in their local or preferred
languages, to undergo a screening ultrasound scan to date
the pregnancies accurately. They enrolled women if the ultrasound-estimated gestational age of the pregnancy was
within the eligibility cut-offs (gestation 8 to <20 weeks).
Women were consented for the screening scan, follow-up
and biosample collection. The fathers of the babies also
consented for their saliva sample collection. These samples

R

Biomaterial collection and biobanking
A sampling scheme with a sequence of time points was
used to obtain maternal blood and urine, maternal stool,
umbilical cord blood and tissue, placenta tissue and
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Island-Tanzania) had their geographical coordinates collected
and linked to a database through a unique identification (ID)
number to allow longitudinal linkages. Trained fieldworkers
(FWs) or community health workers (CHWs), predominantly
women, performed home visits every 2–3 months to all
women of reproductive age in the study area to enquire about
pregnancy. If a woman reported or suspected a pregnancy,
FWs ascertained the gestational age using the date of her last
menstrual bleeding and conducted a urine pregnancy test to
confirm it. Pregnant women who provided consent underwent a screening ultrasound and Hadlock’s criteria were used
to date the pregnancy more precisely.18 All women with early
pregnancies between 8 and 19 weeks of gestation who
intended to stay in the study areas for the entire duration of
follow-up and consented for the collection of epidemiological
data as well as biological samples were included in the
cohort.
The AMANHI biobank cohort includes a total of 10 001
women across sites enrolled between from May 2014 and
June 2018, who have given birth to 9938 babies and had
their epidemiological data and biological samples collected
and stored. The socio-demographic characteristics of the
households and women enrolled in the cohort by site are
presented in Table 1.
After enrolment, trained study FWs (or trained CHWs)
conducted four home visits to all women in the cohort; at
baseline (immediately after enrolment), at 24–28 weeks,
32–36 weeks and after 37 completed weeks of pregnancy
to collect routine study data. During the pregnancy visits,
maternal blood and urine samples were collected. Women
were randomized for antenatal maternal sample collection
at either 24–28 or 32–36 weeks’ gestation at a ratio of 2:1.
Maternal stool, umbilical cord blood and tissue, placenta tissue and membranes, and infant saliva samples
(where cord blood was not available) were obtained at
birth and a delivery form was filled in within 48 hours of
birth. Afterwards, two additional visits were made: one between 1 and 6 days after birth and the second one between
42 and 60 days of age, in which newborn’s blood and stool
samples were taken. Figure 1 shows the flow of participants from enrolment to postnatal visits.
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Table 1 Baseline socio-demographic characteristics of the households from women participating in the AMANHI (Alliance for
Maternal and Newborn Health Improvement) biobank cohort

Number of enrolled women (N)
Woman’s age in current pregnancy (years) [n (%)]
15–19
20–29
30–39
40–49
No data
Gravidity (including current pregnancy) [n (%)]
1
2
3
>4
No data
Parity [n (%)]
First pregnancy
0
1–2
3–4
>5
No data
Woman’s education [n (%)]
No schooling
1–4 years
5–9 years
10þ years
No data
Woman’s occupation [n (%)]
Government/private job, daily wage earner
Self-employed
Farming
Not working outside home
No data
Father’s education [n (%)]
No schooling
1–4 years
5–9 years
10þ years
No data
Number of persons per room in the house [median (IQR)]
Use biomass fuel for cooking [n (%)]
Flush or pour toilet [n (%)]
Households with piped water into the dwelling [n (%)]

Pemba-Tanzania

Karachi-Pakistan

Total

3000

4501

2500

10 001

634 (21.1%)
2004 (66.8%)
353 (11.8%)
5 (0.3%)
4

295 (6.55%)
2429 (53.97%)
1538 (34.17%)
239 (5.31%)
0

197 (7.9%)
1594 (63.8%)
681 (27.2%)
28 (1.1%)
0

1126 (11.3%)
6027 (60.3%)
2572 (25.7%)
272 (2.7%)
4

988 (32.9%)
744 (24.8%)
544 (18.1%)
720 (24.0%)
4

785 (17.5%)
441 (9.8%)
653 (14.6%)
2606 (58.1%)
16

478 (19.1%)
526 (21.0%)
471 (18.8%)
1025 (41.0%)
0

2251 (22.6%)
1711 (17.1%)
1668 (16.7%)
4351 (43.6%)
20

988 (33.0%)
142 (4.7%)
1294 (43.2%)
462 (15.4%)
110 (3.7%)
4

785 (17.5%)
71 (1.6%)
1163 (25.9%)
1072 (23.9%)
1394 (31.1%)
16

478 (19.1%)
157 (6.3%)
1092 (43.7%)
475 (19.0%)
298 (11.9%)
0

2251 (22.6%)
370 (3.7%)
3549 (35.6%)
2009 (20.1%)
1802 (18.1%)
20

190 (6.4%)
278 (9.3%)
2063 (69%)
460 (15.4%)
9

601 (13.4%)
1499 (33.4%)
2304 (51.4%)
81 (1.8%)
16

1306 (52.2%)
162 (6.5%)
597 (23.9%)
435 (17.4%)
0

2097 (21.0%)
1939 (19.4%)
4964 (49.8%)
976 (9.8%)
25

33 (1.1%)
6 (0.2%)
1 (0%)
2955 (98.7%)
5

581 (13.0%)
261 (5.8%)
778 (17.3%)
2865 (63.9%)
16

44 (1.8%)
34 (1.4%)
0 (0%)
2422 (96.9%)
0

658 (6.6%)
301 (3.0%)
779 (7.8%)
8242 (82.6%)
21

485 (16.5%)
594 (20.2%)
1493 (50.8%)
367 (12.5%)
61
1.7 (1.3-2.25)
2933 (97.8%)
1095 (36.6%)
49 (1.6%)

484 (10.8%)
1386 (30.9%)
2491 (55.5%)
124 (2.8%)
16
1.5 (1-2)
3799 (84.4%)
1230 (27.4%)
1508 (33.6%)

1385 (55.4%)
83 (3.3%)
566 (22.6%)
466 (18.6%)
0
3.5 (2.5-4.5)
270 (10.8%)
2483 (99.3%)
1484 (59.4%)

2354 (23.7%)
2063 (20.8%)
4550 (45.9%)
957 (9.6%)
77
2 (1.3-2.7)
7002 (70.0%)
4808 (48.1%)
3041 (30.4%)

IQR, interquartile range.

membranes, newborn stool and saliva samples (where
cord blood was not available) and paternal saliva samples. Standardized protocols for collection, processing
and storage were implemented across all sites, as shown
in Supplementary Table S1, available as Supplementary
data at IJE online, and previously presented in the

methodological paper.17 The biological samples are
stored separately in the AMANHI biobank at each site. In
Bangladesh, the AMANHI biobank is located in Sylhet
and in the North South University, Dhaka. In Pakistan,
the AMANHI biobank is at The Aga Khan University,
Stadium Campus Karachi. In Pemba, it is in CPHK-PHL-
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IdC biorepository situated at Public Health LaboratoryIvo de Carneri (PHL-IdC) Campus, Wawi, Chake district
of Pemba Island Zanzibar.
During the enrolment visit, blood was drawn for all
participating women and a urine sample was collected
(Table 3). The blood was collected into pre-labelled
tubes, centrifuged and serum, plasma and buffy-coat aliquots were obtained. Maternal urine samples (n ¼ 10
001) were similarly centrifuged and RNALater was mixed
with sediments and aliquots taken for storage. Maternal
blood and urine samples were taken at either the 24–28
or 32–36 weeks’ (blood samples: n ¼ 9134; urine samples:
n ¼ 9141) pregnancy visit and after 42 days of the delivery
(blood samples: n ¼ 8743; urine samples: n ¼ 8746).
At birth, 7435 placenta samples were collected, and
5456 fresh and 1461 clotted cord blood samples extracted.

Placenta samples were harvested and processed within
30 minutes of delivery. Full-thickness tissue samples were
harvested in four areas, three of which have a thin layer of
maternal tissues sliced off the surface. Placental tissue samples were stored in RNALater, Formalin, and were flashfrozen.
A total of 8651 maternal stool samples were collected
to assess the microbiota at the time of delivery and 7797
newborn stool samples were collected when feeding
started. A single sample of paternal saliva (during one of
the pregnancy visits or during the postnatal period) and
newborn saliva (between 42 and 60 days post-partum from
babies whose cord blood could not be obtained at the time
of birth) were collected using an Oragene DNA collection
kit for DNA extraction. All biological samples were processed and stored at –80 C.
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Table 2 Summary of the obstetric history and current risk factors of women participating in the AMANHI (Alliance for Maternal
and Newborn Health Improvement) biobank cohort

Number of women with a previous pregnancy (N)
Age at first pregnancy [median (IQR)]
ANC in previous pregnancies:
Attended ANC in all previous pregnancies
Attended ANC in some of the previous pregnancies
No ANC in the previous pregnancies
No data
History of miscarriage
Number of women with a previous pregnancy that
finished in a birth (N)
History of stillbirth
History of caesarean sections
History of severe bleeding or haemorrhage before delivery
History of severe bleeding or haemorrhage after delivery
History of premature birth
History of multiple pregnancies (twins or triplets)
History of pre-eclampsia/eclampsia
Women who have had any babies with birth defects
Women with self-reported illness before current pregnancy (N)
Diabetes
Thyroid disease
Cardiac disease
Epilepsy
Hypertension
HIV/AIDS
Tuberculosis
Woman’s risk factors and exposures during current pregnancy (N)
Woman’s BMI (kg/m2)
Underweight (<18.5)
Normal weight (18.5–24.9)
Overweight (25.0–29.9)
Obesity (>30.0)
No data
Woman’s height (cm) [mean (SD)]
Ever use tobacco (smoke or sniffed/chewed tobacco)
Second-hand smokinga
Ever consume alcohol

Total

2008
18 (18-20)

3716
19 (17-21)

2022
19 (17-22)

7746
19 (18-21)

671 (33.4%)
788 (39.2%)
549 (27.3%)
0
382 (19.0%)
1931

3379 (91.3%)
311 (8.4%)
10 (0.3%)
16
805 (21.7%)
3716

1216 (60.1%)
636 (31.5%)
170 (8.4%)
0
746 (36.9%)
1904

5266 (68.1%)
1735 (22.5%)
729 (9.4%)
16
1933 (25.0%)
7461

235 (12.2%)
62 (3.2%)
14 (0.7%)
22 (1.1%)
108 (5.6%)
28 (1.5%)
3 (0.2%)
25 (1.3%)
3000
10 (0.3%)
3 (0.1%)
4 (0.1%)
11 (0.4%)
7 (0.2%)
0 (0%)
6 (0.2%)
3000

360 (9.7%)
118 (3.2%)
141 (3.8%)
253 (6.8%)
112 (3.0%)
119 (3.2%)
53 (1.4%)
137 (3.7%)
4501
25 (0.6%)
11 (0.3%)
22 (0.5%)
24 (0.6%)
130 (3.1%)
7 (0.2%)
18 (0.4%)
4501

160 (8.4%)
192 (10.1%)
41 (2.2%)
41 (2.2%)
177 (9.3%)
26 (1.4%)
37 (1.9%)
54 (2.9%)
2500
19 (0.8%)
12 (0.5%)
7 (0.3%)
2 (0.1%)
143 (5.7%)
3 (0.1%)
32 (1.3%)
2500

755 (10.1%)
372 (5.0%)
196 (2.6%)
316 (4.2%)
397 (5.3%)
173 (2.3%)
93 (1.2%)
216 (2.9%)
10 001
54 (0.5%)
26 (0.3%)
33 (0.3%)
37 (0.4%)
280 (2.8%)
10 (0.1%)
56 (0.6%)
10 001

964 (32.5%)
1807 (60.9%)
165 (5.6%)
31 (1.0%)
33
149.7 (5.4)
511 (17.0%)
2365 (78.9%)
0 (0.0)

251 (6.3%)
2149 (53.6%)
960 (23.9%)
652 (16.2%)
489
155.3 (6.3)
32 (0.8%)
1054 (23.4%)
3 (0.1%)

518 (22.1%)
1208 (51.6%)
439 (18.8%)
175 (7.5%)
160
153.7 (6.5)
503 (20.1%)
727 (29.1%)
32 (1.3%)

1733 (18.6%)
5164 (55.4%)
1564 (16.8%)
858 (9.2%)
682
153.1 (6.5)
1046 (10.5%)
4146 (41.5%)
35 (0.3%)

a
We defined second-hand smoking as having lived with a smoker in the same room or compound.
ANC, antenatal care; BMI, body mass index; IQR, interquartile range; SD, standard deviation.

What has been found?
So far, data from the AMANHI biobank study have been
analysed to examine socio-demographic characteristics,
obstetric history, maternal morbidities and birth outcomes.
We identified 10 001 pregnancies across the study sites,
with outcomes ascertained for 9921 (99.2%), including
143 (1.4%) miscarriages or induced abortions occurring
after enrolment (from 8 to <22 weeks of gestational age)
and 8 pregnancy-related death occurring before delivery.
The remaining 9850 pregnancies resulted in a total of 9938

births, with 9576 live-born babies and 362 stillbirths
(4%). There was a total of 32 pregnancy-related deaths
(deaths during pregnancy, childbirth and within 42 days
post-partum).
The proportion of maternal morbidities varied widely
across study sites, ranging from 9% of women with at least
one pregnancy-related morbidity in Bangladesh to 41% in
Karachi. This variation was mainly driven by the high incidence of infections in the antepartum and post-partum
periods in Karachi (23% and 13%, respectively) in
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Table 3 Numbers of blood, urine, saliva, stool and placental samples per study site
Sample type

Maternal blooda

Maternal urinea

Faecesb
Placentac
Cord bloodc
Saliva

Enrolment (8 to <20
weeks)
Pregnancy visit 2 or
pregnancy visit 3
Visit during postnatal period (42 days
post-partum)
Enrolment (8 to <20
weeks)
Pregnancy visit 2 or
pregnancy visit 3
Visit during postnatal period (42 days
post-partum)
Maternal
Newborn
Placenta
Fresh cord blood
Clotted cord bloode
Newbornd
Paternal

Sylhet-Bangladesh
n/N (%)

Pemba-Tanzania
n/N (%)

Karachi-Pakistan
n/N (%)

Total
n/N (%)

2999/3000 (100%)

4501/4501 (100%)

2500/2500 (100%)

10000/10001 (100%)

2760/2958 (93.3%)

4170/4423 (94.3%)

2204/2427 (90.8%)

9134/9808 (93.1%)

2529/2731 (92.6%)

4007/4473 (89.6%)

2207/2330 (94.7%)

8743/9534 (91.7%)

3000/3000 (100%)

4501/4501 (100%)

2500/2500 (100%)

10 001/10 001 (100%)

2767/2958 (93.5%)

4170/4423 (94.3%)

2204/2427 (90.8%)

9141/9808 (93.2%)

2534/2731 (92.8%)

4007/4473 (89.6%)

2205/2330 (94.6%)

8746/9534 (91.7%)

2581/3000 (86%)
2213/2858 (77.4%)
2532/2964 (85.4%)
1488/2964 (50.2%)
567/2964 (19.1%)
553/2858 (19.3%)
2384/3000 (79.5%)

3869/4440 (86%)
3585/4366 (82.1%)
4095/4443 (92.2%)
3674/4443 (82.7%)
377/4443 (8.5%)
206/4366 (4.7%)
3858/4501 (85.7%)

2201/2287 (96.2%)
1999/2205 (90.7%)
808/2325 (34.8%)
294/2325 (12.6%)
517/2325 (22.2%)
1413/2325 (60.8%)
2319/2500 (92.8%)

8651/9727 (88.9%)
7797/9429 (82.7%)
7435/9732 (76.4%)
5456/9732 (56.1%)
1461/9732 (15.0%)
2172/9549 (22.7%)
8561/10 001 (85.6%)

a
To calculate the proportion of maternal blood and urine samples collected during the pregnancy visits, the denominator is the total number of women still pregnant in the cohort at the time of the visit. For the maternal samples collected in the postnatal period, the denominator corresponds to the total number of women
who had a stillbirth or live birth.
b
To calculate the proportion of newborn faeces collected, we included all babies born alive in the denominator.
c
To calculate the proportion of placenta and cord blood samples collected, we considered all pregnancies that ended in delivery as the denominator.
d
Collected only if cord blood could not be collected.
e
Collected only if fresh cord blood could not be collected.

comparison with the other two sites. Pregnancy-related hypertension was the most common cause of maternal morbidity in Pemba and Karachi. Substantial differences were
found in the burden of pre-eclampsia/eclampsia when analysing by region, being over 6-fold higher in the African
site in comparison with the Asian sites. Table 4 presents
the distribution of these morbidities by site. Of the 1517
women with some morbidity, 76% (n ¼ 1146) had only
one whereas the remaining 24% (n ¼ 371) had two or
more.
Karachi experienced the highest number of postenrolment miscarriages with 20 miscarriages per 1000
pregnancies in comparison with 12 and 13 per 1000
pregnancies in Bangladesh and Tanzania, respectively.
On the contrary, the number of pregnancy-related deaths
(PRDs) in Karachi was 240 per 100 000 pregnancies,
representing two-thirds of the PRDs in Pemba (378 per
100 000 pregnancies). Of all PRDs, 25% occurred
before labour and the remaining 75% during labour,
between birth and 24 hours, or within 42 days postpartum.

From all births, 9576 resulted in a live baby (96%),
with clear variations in the neonatal outcomes across
regions. Those babies born in Bangladesh and Pakistan
were born earlier and with a lower weight than the babies
born in Pemba. The incidence of prematurity (<37 weeks
of gestational age) was, on average, double in Asia (15%)
compared with that in Africa (7%). The same relation was
present for birthweight, with 27% of live babies born
weighing <2500 g in Asia vs 7% in Africa. When analysing
the relationship between birth and time of gestation,
Bangladesh had the highest proportion of small-for-gestational-age babies (SGA: 46%).
Overall, the proportion of premature births due to premature ruptures of the membranes (PPROM) was 20% of all
preterm births, 75% from spontaneous preterm labour and
only 5% because of a medically indicated caesarean section.
Neonatal deaths varied widely per region, with 47 neonatal deaths per 1000 live births in Bangladesh, 39 per
1000 live births in Pakistan and 20 per 1000 live births in
Tanzania. Site-specific pregnancy and neonatal outcomes
are shown in Table 5.
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Table 4 Pregnancy characteristics and women’s morbidities during current pregnancy
Pemba-Tanzania

Karachi- Pakistan

Total

3000
23.5 (4.4)
27 (0.9%)
2958

4501
27.9 (6.3)
90 (2.0%)
4415

2500
26.6 (5.2)
20 (0.8%)
2426

10 001
26.3 (5.8)
137 (1.4%)
9799

2035 (68.9%)
891 (30.2%)
29 (1.0%)
0

3549 (83.0%)
720 (16.8%)
8 (0.2%)
138

1568 (67.8%)
725 (31.3%)
21 (0.9%)
112

7152 (74.9%)
2336 (24.5%)
58 (0.6%)
250

2510 (85.3%)
18 (0.6%)
415 (14.1%)
12

4099 (95.8)
10 (0.2%)
168 (3.9%)
138

1856 (80.1%)
63 (2.7%)
399 (17.2%)
108

8465 (88.7%)
91 (1.0%)
982 (10.3%)
258

354 (12.0%)
1671 (56.8%)
767 (26.1%)
78 (2.7%)
58 (2.0%)
15 (0.5%)
12
3000
21 (0.7%)
52 (1.9%)

314 (7.3%)
2915 (68.2%)
644 (15.1%)
397 (9.3%)
7 (0.2%)
0 (0%)
138
4501
61 (1.4%)
21 (0.5%)

1129 (49.4%)
551 (24.1%)
576 (25.2%)
0 (0%)
25 (1.1%)
5 (0.2%)
140
2500
145 (5.9%)
532 (22.8%)

1797 (18.9%)
5137 (54.0%)
1987 (20.9%)
475 (5.0%)
90 (0.9%)
20 (0.2%)
290
10 001
227 (2.3%)
605 (6.0%)

104 (3.5%)
5 (0.2%)
1 (0%)
14 (0.5%)
94 (3.4%)

603 (13.7%)
175 (3.9%)
4 (0.1%)
35 (0.9%)
141 (3.5%)

243 (10%)
15 (0.6%)
0 (0%)
33 (1.4%)
298 (12.8%)

950 (9.5%)
195 (1.9%)
5 (0.0%)
82 (0.8%)
533 (5.3%)

a
Denominators include all pregnancies that ended in the delivery of either a stillbirth or a live birth.
PRD, pregnancy-related deaths; SD, standard deviation.

What are the main strengths and
weaknesses?
The AMANHI biobank is the first population-based repository of biological samples established in sub-Saharan
Africa and South Asia—two regions that bear a substantial portion of the total global burden of maternal deaths,
stillbirths and neonatal deaths. During this study, we collected extensive data on socio-economic and household
characteristics, clinical and obstetric history, and maternal morbidities and phenotypical data by systematic and
prospective follow-up. In addition, we documented a
multiplicity of outcomes from the mother, the fetus and
the neonate, opening opportunities to explore an array of
new hypotheses. The high follow-up rates allowed the
collection of large number of samples from pregnancy to
delivery up to 42 days post-partum. The extraction of

these samples followed a harmonized process, including
the use of uniform protocols; the centralized procurement
of equipment, materials and reagents; and the strict and
rigorous quality-control measures that allow the comparability of data across all sites. To ensure a thorough process and reduce transcription errors, samples have been
time-stamped and barcoded by a computer, and all metadata are available for analysis. The AMANHI biobank
can be used as a platform for further exploration of new
hypotheses and technologies, and to build local capacity
in these low-resource settings for high-quality research
and ultra-high-throughput analyses.
Although we had a limited number of pregnancies per
site, we were able to collect harmonized samples from
10 001 pregnant women and their offspring, which will
allow pooling and consequent use in the analyses of less
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Current pregnancy and delivery characteristics (N)
Women’s age at time of pregnancy [mean (SD)]
Multiple pregnancies [n (%)]
Pregnancies that ended in delivery (excluding miscarriages
and PRD before delivery) (N)
Place of delivery [n (%)]a
Facility/hospital
Home/compound
Other
Missing
Delivery mode [n (%)]a
Vaginal
Vaginal assisted (e.g. forceps, vacuum)
Caesarean section
Missing
Person assisting the delivery [n (%)]a
Doctor
Midwife/nurse
Traditional birth attendant
Other health professional
Relative/friend
None, woman herself
Missing
Women morbidity during current pregnancy (N)
Severe antepartum haemorrhage [n (%)]
Late antepartum infection [n (%)]
Hypertensive disorders of pregnancy [n (%)]
Gestational hypertension
Pre-eclampsia
Eclampsia
Post-partum haemorrhage [n (%)]
Post-partum infection [n (%)]

Sylhet-Bangladesh
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Table 5 Pregnancy and birth outcomes per study site

Gestational age
at birth among
live births

Birthweight
among live
births

Birthweight-forgestational age
at birth among
live birth
Deaths in the
cohortb

PRD [n/N (rate per 100 000
pregnancies)]
Miscarriage [n/N (rate per 1000
pregnancies)]a
Stillbirths [n/N (rate per 1000
births)]
Live births [n/N (rate per 1000
births)]
Early preterm, <34 weeks [n
(%)]
Late Preterm, 34–36 weeks [n
(%)]
Term, 37 weeks [n (%)]
No data on gestational age
Low birthweight (<2500 g) [n
(%)]
Normal birthweight (2500 g)
[n (%)]
No data on birthweight
Small for gestational age [n (%)]
Appropriate for gestational age
[n (%)]
Large for gestational age [n (%)]
No data
Early neonatal deaths [n (rate
per 1000 live births)]
Late neonatal death [n (rate per
1000 live births)]

Pemba-Tanzania

Karachi- Pakistan

9/3000 (300)

17/4501 (378)

6/2500 (240)

Total
32/10 001 (320)

36/3000 (12)

58/4501 (13)

49/2500 (20)

143/10 001 (14)

127/2985 (43)

141/4507 (31)

94/2446 (38)

362/9938 (36)

2858/2985 (957)

4366/4507 (969)

2352/2446 (962)

9576/9938 (964)

87 (3.0%)

81 (1.9%)

72 (3.1%)

240 (2.5%)

276 (9.7%)

224 (5.3%)

312 (13.3%)

812 (8.6%)

2495 (87.3%)
0
713 (30.1%)

3954 (92.8%)
107
261 (6.5%)

1967 (83.7%)
1
497 (23.4%)

8416 (88.9%)
108
1471 (17.3%)

1656 (69.9%)

3773 (93.5%)

1624 (76.6%)

7053 (82.7%)

489
1089 (46.0%)
1289 (52.7%)

332
408 (10.2%)
3083 (77.3%)

231
690 (33.2%)
1319 (63.5%)

1052
2187 (25.8%)
5691 (67.0%)

31 (1.3%)
489
113 (40)

511 (12.8%)
361
77 (18)

69 (3.3%)
274
77 (33)

611 (7.2%)
1124
267 (28)

21 (7)

10 (2)

14 (6)

45 (5)

a

The cut-off point for miscarriage/abortion was 22 weeks of gestational age.
Early neonatal deaths include those deaths that occurred between days 0 and 6 of life, whereas late neonatal death occurred between days 7 and 28.
PRD, pregnancy-related deaths.

b

frequent outcomes. Despite taking all methodological
measures to collect the most adequate samples to conduct analyses of data from whole-genome arrays, not all
analyses will be possible, as specific assays might have
requirements that were not considered during the preparation of this study. Moreover, unlike biobanks in many
HICs, we had to reduce the volume of blood per sample,
which will affect the final number of aliquots available
for analysis. Finally, despite having a well-characterized
population-based cohort in these LMICs, it does not inform on the biological mechanisms underlying childhood
linear growth and neurodevelopment. A continuation of
the cohort following up the children into their second and
third years after birth is now ongoing (All Children
Thrive- ACT- study) and will be published separately.
The ACT study will provide opportunities to examine epigenetic factors in pregnancy or early childhood that could
predict stunting and impaired neurodevelopment—the

origins and risk factors of susceptibility to infectious
agents and non-communicable diseases.

Can I get hold of the data? Where can I find
out more?
Establishing this biobank is only the first step and will be
of little value if it is not utilized to address current global
challenges. The AMANHI biobank data are available at
the Department for Maternal, Newborn, Child, and
Adolescents Health, and Ageing at the WHO, which is the
coordination centre of the study. Queries regarding the
data and potential collaborations can be sent to Dr Rajiv
Bahl (bahlr@who.int). To access the data, a formal application must be submitted with a detailed research proposal
consisting of the proposed title, authors, affiliations, research question, brief scientific background of 200
words, study design, study population with details on
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